Brandy Richards
Primary Care · Cleveland, OHNPI 1770037343
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 82 payments — averaging $97.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- E.r. Squibb & Sons, L.L.C.$694
- AbbVie$673
- Otsuka America Pharmaceutical, Inc.$554
- Axsome Therapeutics, Inc.$491
- Alkermes, Inc.$419
- plus $4K from 22 others
What the payments were for
- Food & beverage$7,87899%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 12 | $1,527 |
| E.r. Squibb & Sons, L.L.C. | 6 | $694 |
| AbbVie | 6 | $673 |
| Otsuka America Pharmaceutical, Inc. | 6 | $554 |
| Axsome Therapeutics, Inc. | 4 | $491 |
| Alkermes, Inc. | 4 | $419 |
| AstraZeneca(2 entities) | 3 | $384 |
| Sanofi | 3 | $369 |
| Novo Nordisk | 3 | $280 |
| Ferring Pharmaceuticals Inc. | 2 | $264 |
| Viiv Healthcare Company | 2 | $250 |
| Indivior Inc. | 10 | $224 |
| Biogen | 2 | $200 |
| Gilead | 2 | $180 |
| Alnylam Pharmaceuticals Inc. | 2 | $146 |
| Hologic Sales And Service, LLC | 1 | $131 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| SK Life Science, Inc. | 1 | $125 |
| Xeris Pharmaceuticals, Inc. | 1 | $125 |
| Teva Pharmaceuticals USA, Inc. | 1 | $125 |
| Sage Therapeutics, LLC | 1 | $111 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $107 |
| Pfizer | 1 | $100 |
| Exact Sciences | 2 | $99 |
| Inspire Medical Systems, Inc. | 1 | $88 |
| Edwards Lifesciences | 1 | $88 |
| Neurelis, Inc. | 1 | $64 |
| Abbott | 2 | $35 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,293
- INVEGA SUSTENNA$1,160
- COBENFY$598
- INVEGA TRINZA$544
- Auvelity$491
- VRAYLAR$352
- REBYOTA$264
- REXULTI$245
- Aptima$131
- VOQUEZNA$125
- FASENRA$125
- XCOPRI$125
- GVOKE HYPOPEN$125
- ABILIFY MAINTENA$125
- APRETUDE$125
- DOVATO$125
- UZEDY$125
- Mavyret$112
- GIVLAARI$110
- ARCALYST$107
How this compares
$7,978 in reported general payments places this provider in the 95th percentile of 321 primary care providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SublocadeBuprenorphine | 19 | $36,483 |
| VivitrolNaltrexone Microspheres | 22 | $29,996 |
| VraylarCariprazine Hcl | 14 | $20,026 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 87 | $9,517 |
| Fluoxetine Hcl | 13 | $536 |
| Bupropion XlBupropion Hcl | 26 | $530 |
| Trazodone Hcl | 31 | $468 |
| Naltrexone Hcl | 18 | $462 |
| Mirtazapine | 24 | $310 |
| Buspirone Hcl | 12 | $247 |
| Quetiapine Fumarate | 18 | $232 |
| Clonidine Hcl | 21 | $158 |
| Hydroxyzine Pamoate | 17 | $142 |
| Escitalopram Oxalate | 19 | $65 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Indivior Inc.Sublocade | $224 | $36,48319 claims |
| Alkermes, Inc.Vivitrol | $419 | $29,99622 claims |
| AbbVieVraylar | $673 | $20,02614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 321 primary care providers in Ohio.
Other primary care in Cleveland
- Andjelina PupovacCleveland$2K
- Camille SterlingCleveland$2K
- Danielle ModloCleveland$2K
- Adine EdwardsSpringfield$14K
- Kelly McKenna TaulbeeHamilton$12K
- Lindsay ChappellFairlawn$11K
- Laura HolligerNorth Canton$10K
- Caitlyn FrantzDayton$10K
- Regan HeagenFindlay$8K
- Zachary HaleBeavercreek$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.